Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection technology, today announced the presentation of multiple lymphoma studies featuring Foresight CLARITY(TM) ...

SAGA Diagnostics, a pioneer in blood-based cancer detection and precision medicine redefining the standard for ultra-sensitive and early molecular residual disease (MRD) detection, will present five ...

According to the World Health Organization, cancer diagnoses remain a leading cause of death. However, scientific and medical communities have improved clinical outcomes for many people, transforming ...

MRD detection via ctDNA poses challenges in managing breast cancer patients in complete remission, especially when imaging is ...

OGT launches the SureSeq Myeloid MRD Plus Panel, enabling ultra-sensitive MRD detection in AML with variant calls down to ...

Minimal residual disease (MRD)—minute populations of cancer cells undetectable by conventional imaging—remains the chief ...

A recent review outlined advances and challenges in utilizing liquid biopsy to detect measures such as circulating tumor DNA in patients with solid tumors. MRD refers to the presence of residual ...

We hypothesized that circulating tumor DNA (ctDNA) molecular residual disease (MRD) analysis without prior mutational knowledge could be performed after neoadjuvant chemotherapy to assess ...

Studies across all breast-cancer subtypes confirm Pathlight’s ultra-sensitive performance for early recurrence detection and treatment-response monitoringMORRISVILLE, N.C.--(BUSINESS ...

Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection technology, today announced the presentation of multiple lymphoma studies featuring Foresight CLARITY™ ...